A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer (H-52350)

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer

The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application. Participants must have a confirmed diagnosis urothelial carcinoma of the bladder without metastatic disease.

For more information: https://clinicaltrials.gov/study/NCT05483868